Join the Ocrevus Zunovo group to help and get support from people like you.
Ocrevus Zunovo News
FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
South San Francisco, CA – September 13, 2024 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has...
FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS
THURSDAY, Sept. 26, 2024 – The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection...